Delayed
Toronto S.E.
10:54:46 2023-05-05 am EDT
|
5-day change
|
1st Jan Change
|
0.04
CAD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
114.8
|
123.6
|
56.52
|
37.61
|
Enterprise Value (EV)
1 |
98.36
|
90.43
|
51.14
|
30.92
|
P/E ratio
|
-3.75
x
|
-2.94
x
|
-1.88
x
|
-1.04
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
128,763,858
x
|
12,899,638
x
|
7,049,882
x
|
2,939,788
x
|
EV / Revenue
|
110,310,331
x
|
9,437,264
x
|
6,378,653
x
|
2,416,458
x
|
EV / EBITDA
|
-5.16
x
|
-2.55
x
|
-2.23
x
|
-1.57
x
|
EV / FCF
|
-9,194,762
x
|
-4,453,326
x
|
-1,603,266
x
|
-2,692,729
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
4.5
x
|
1.76
x
|
0.89
x
|
1.13
x
|
Nbr of stocks (in thousands)
|
75,043
|
116,612
|
150,717
|
179,117
|
Reference price
2 |
1.530
|
1.060
|
0.3750
|
0.2100
|
Announcement Date
|
4/30/19
|
5/1/20
|
4/29/21
|
4/29/22
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
|
-
|
0.8917
|
9.582
|
8.017
|
12.8
|
EBITDA
1 |
-4.517
|
-19.04
|
-35.48
|
-22.98
|
-19.72
|
EBIT
1 |
-4.518
|
-19.38
|
-35.98
|
-23.6
|
-20.52
|
Operating Margin
|
-
|
-2,172.89%
|
-375.48%
|
-294.44%
|
-160.4%
|
Earnings before Tax (EBT)
1 |
-4.535
|
-19.73
|
-36.36
|
-23.95
|
-33.59
|
Net income
1 |
-4.535
|
-19.81
|
-36.38
|
-24.04
|
-33.13
|
Net margin
|
-
|
-2,221.27%
|
-379.63%
|
-299.85%
|
-258.92%
|
EPS
2 |
-0.1634
|
-0.4082
|
-0.3600
|
-0.2000
|
-0.2014
|
Free Cash Flow
|
-
|
-10.7
|
-20.31
|
-31.9
|
-11.48
|
FCF margin
|
-
|
-1,199.71%
|
-211.91%
|
-397.85%
|
-89.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/15/18
|
4/30/19
|
5/1/20
|
4/29/21
|
4/29/22
|
Fiscal Period: December |
2020 Q2
|
2020 Q3
|
2020 Q4
|
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
1.67
|
1.928
|
2.518
|
2.837
|
2.803
|
3.519
|
3.636
|
4.643
|
4.473
|
3.385
|
EBITDA
1 |
-3.855
|
-4.706
|
-5.805
|
-4.019
|
-3.85
|
-3.772
|
-5.649
|
-3.057
|
-2.288
|
-2.831
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/24/20
|
11/30/20
|
4/29/21
|
5/27/21
|
8/23/21
|
11/22/21
|
4/29/22
|
5/30/22
|
8/26/22
|
11/30/22
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1.81
|
16.5
|
33.2
|
5.38
|
6.7
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-10.7
|
-20.3
|
-31.9
|
-11.5
|
ROE (net income / shareholders' equity)
|
-
|
-143%
|
-76.1%
|
-36.1%
|
-68.6%
|
ROA (Net income/ Total Assets)
|
-
|
-56%
|
-36.8%
|
-19%
|
-22.2%
|
Assets
1 |
-
|
35.37
|
98.89
|
126.4
|
149.1
|
Book Value Per Share
2 |
0.0700
|
0.3400
|
0.6000
|
0.4200
|
0.1900
|
Cash Flow per Share
2 |
0.0600
|
0.2000
|
0.0800
|
0.0500
|
0.0500
|
Capex
1 |
0.29
|
3.83
|
6.09
|
2.69
|
1.74
|
Capex / Sales
|
-
|
429.06%
|
63.6%
|
33.59%
|
13.63%
|
Announcement Date
|
5/15/18
|
4/30/19
|
5/1/20
|
4/29/21
|
4/29/22
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 6.81M | | +44.36% | 6.34B | | -13.52% | 4.61B | | +10.85% | 3.39B | | -6.52% | 3.29B | | +51.14% | 2.02B | | -5.22% | 1.73B | | +1.29% | 1.67B | | +57.69% | 1.63B | | -9.67% | 1.59B |
Alternative Medicine
|